POMALIDOMIDE
Clinical safety rating
cautionComprehensive clinical and safety monograph for POMALIDOMIDE (POMALIDOMIDE).
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
| Metabolism | Primarily metabolized by CYP1A2 and CYP3A4; undergoes glucuronidation via UGT1A8. |
| Excretion | Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal). |
| Half-life | Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment. |
| Protein binding | 12-44% bound to albumin and alpha-1-acid glycoprotein; mean ~30%. |
| Volume of Distribution | 62-138 L (approx 0.8-1.7 L/kg); indicates extensive tissue distribution. |
| Bioavailability | Oral: 73% (range 56-85%); high fat meal reduces AUC by 13% but no significant effect. |
| Onset of Action | Oral: 2-4 weeks for hematologic response in multiple myeloma. |
| Duration of Action | Not formally established; continuous therapy until disease progression or unacceptable toxicity; immunomodulatory effects persist days after last dose. |
| Molecular Weight | 273.24 |
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
| Dosage form | CAPSULE |
| Renal impairment | CrCl 30-59 mL/min: 3 mg once daily. CrCl <30 mL/min: 2 mg once daily. Not recommended if CrCl <15 mL/min or requiring dialysis. |
| Liver impairment | Child-Pugh A: 4 mg once daily. Child-Pugh B: 2 mg once daily. Child-Pugh C: 1 mg once daily. |
| Pediatric use | Safety and efficacy not established; no recommended dosing. |
| Geriatric use | No specific dose adjustment; monitor for increased toxicity (e.g., myelosuppression, neurotoxicity) due to age-related organ function decline. |
| 1st trimester | Pomalidomide is an analogue of thalidomide, a known human teratogen. It causes severe life-threatening birth defects or fetal death in animal studies. Therefore, it is contraindicated in pregnancy and should not be used in the first trimester. Women of childbearing potential must use effective contraception and have negative pregnancy tests before and during therapy. |
| 2nd trimester | Contraindicated in pregnancy due to teratogenicity. Use only if the benefit outweighs the risk, but pomalidomide is not recommended in any trimester. If used, the patient must be enrolled in a pregnancy prevention program. |
| 3rd trimester | Contraindicated in pregnancy due to teratogenicity and potential fetal harm. Use only if the benefit outweighs the risk and with strict pregnancy prevention measures, but pomalidomide is not recommended in any trimester. |
Clinical note
Comprehensive clinical and safety monograph for POMALIDOMIDE (POMALIDOMIDE).
| Placental transfer | Pomalidomide is structurally related to thalidomide, which is known to cross the placenta. Animal studies have shown that pomalidomide is teratogenic and can cause fetal malformations. Likely significant placental transfer in humans, but specific data are limited. |
| Breastfeeding | It is unknown whether pomalidomide is excreted in human milk. However, due to the potential for serious adverse reactions in nursing infants, including teratogenicity and hematologic toxicity, breastfeeding is not recommended during treatment and for at least 4 weeks after the last dose. |
| Lactation Rating | L5 (Avoid) |
| Teratogenic Risk | First trimester: High risk of severe birth defects (e.g., limb anomalies, neural tube defects) due to potent teratogenicity; absolutely contraindicated. Second/third trimester: Risk of fetal harm persists; no safe level established; discontinue if possible. |
| Fetal Monitoring | Pregnancy test before start, weekly during first month, then monthly; confirm negative test before each cycle; monitor for fetal growth (ultrasound) if exposure occurs; complete blood counts (CBC) and liver/renal function tests monthly; ECG for QT prolongation if risk factors. |
| Fertility Effects | May impair male fertility via spermatogenesis disruption; reversible upon discontinuation; females: possible anovulation; recommend fertility preservation counseling before treatment. |
■ FDA Black Box Warning
WARNING: EMBRYO-FETAL TOXICITY, VENOUS AND ARTERIAL THROMBOEMBOLISM, HEPATOTOXICITY, and INCREASED MORTALITY IN MULTIPLE MYELOMA. Pomalidomide is contraindicated in pregnant women due to teratogenicity. Thromboembolic events (DVT, PE, MI, stroke) are increased. Hepatotoxicity may be severe. In multiple myeloma clinical trials, pomalidomide/dexamethasone was associated with increased mortality in patients with high-risk cytogenetics (del 17p, t(4;14), t(14;16)).
| Common Effects | Fatigue Fever Bone pain Muscle cramp Diarrhea Nausea Constipation Breathing problems Cough Decreased appetite Decreased white blood cell count neutrophils Low blood platelets Decreased white blood cell count lymphocytes Anemia low number of red blood cells |
| Serious Effects |
PregnancyWomen of childbearing potential who are not using effective contraceptionHypersensitivity to pomalidomide or any of its excipients
| Precautions | Embryo-fetal toxicity (must use contraception); venous/arterial thromboembolism (consider prophylaxis); hepatotoxicity (monitor LFTs); increased mortality in high-risk multiple myeloma; hematologic toxicity (neutropenia, thrombocytopenia); cardiac toxicity (arrhythmias, heart failure); severe cutaneous reactions; tumor lysis syndrome; renal impairment; fetal risk during pregnancy; avoid use in patients with prior hypersensitivity to thalidomide analogs. |
| Food/Dietary | Avoid grapefruit juice and grapefruit products. Take with water, not with food to reduce nausea. |
| Clinical Pearls | Thromboprophylaxis with aspirin or low molecular weight heparin is mandatory due to high VTE risk. Monitor CBC and thyroid function monthly. Contraindicated in pregnancy due to teratogenicity. Pomalidomide requires REMS program enrollment. Dose reduction needed for renal impairment (CrCl <45 mL/min). |
| Patient Advice | Do not become pregnant while taking this drug; use two reliable forms of contraception. · Report any signs of bleeding or bruising, as pomalidomide can cause low platelet counts. · Avoid grapefruit and grapefruit juice as they may increase drug levels. · Take capsules whole, not crushed or chewed, with water. · Do not donate blood during treatment and for 4 weeks after stopping. |
Loading safety data…